Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of the two firms.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Alexion Pharmaceuticals Inc.||127||5.42||N/A||5.49||20.63|
|Intercept Pharmaceuticals Inc.||92||9.85||N/A||-10.75||0.00|
Table 1 demonstrates Alexion Pharmaceuticals Inc. and Intercept Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 demonstrates the net margins, return on assets and return on equity of Alexion Pharmaceuticals Inc. and Intercept Pharmaceuticals Inc.
|Net Margins||Return on Equity||Return on Assets|
|Alexion Pharmaceuticals Inc.||0.00%||14%||9.5%|
|Intercept Pharmaceuticals Inc.||0.00%||-615.8%||-60.3%|
Volatility & Risk
Alexion Pharmaceuticals Inc.’s current beta is 1.65 and it happens to be 65.00% more volatile than S&P 500. Competitively, Intercept Pharmaceuticals Inc.’s 31.00% volatility makes it more volatile than S&P 500, because of the 1.31 beta.
Alexion Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 4 and 3.6 respectively. The Current Ratio and Quick Ratio of its competitor Intercept Pharmaceuticals Inc. are 3.7 and 3.7 respectively. Alexion Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Intercept Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc. and Intercept Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Alexion Pharmaceuticals Inc.||0||1||3||2.75|
|Intercept Pharmaceuticals Inc.||1||4||9||2.64|
Alexion Pharmaceuticals Inc.’s consensus price target is $161, while its potential upside is 48.13%. Intercept Pharmaceuticals Inc. on the other hand boasts of a $159.87 consensus price target and a 142.63% potential upside. The results from earlier shows that analysts opinion suggest that Intercept Pharmaceuticals Inc. seems more appealing than Alexion Pharmaceuticals Inc.
Insider and Institutional Ownership
Roughly 98.8% of Alexion Pharmaceuticals Inc. shares are owned by institutional investors while 73.2% of Intercept Pharmaceuticals Inc. are owned by institutional investors. 0.3% are Alexion Pharmaceuticals Inc.’s share owned by insiders. Competitively, insiders own roughly 2.4% of Intercept Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Alexion Pharmaceuticals Inc.||-6.35%||-13.7%||-15.54%||-6.62%||-13.85%||16.36%|
|Intercept Pharmaceuticals Inc.||-8.03%||-20.61%||-26.77%||-45.89%||-29.32%||-37.64%|
For the past year Alexion Pharmaceuticals Inc. had bullish trend while Intercept Pharmaceuticals Inc. had bearish trend.
Alexion Pharmaceuticals Inc. beats Intercept Pharmaceuticals Inc. on 8 of the 10 factors.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.